This press release contains "forward-looking statements", including but not limited to the statements by Mr. Ingram, Professor Christopher Chapple and other statements regarding research and development outcomes, efficacy, adverse reactions, market and product potential, product availability and other statements regarding idiopathic overactive bladder and BOTOX(R). These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialise, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include, among other things, general industry and pharmaceutical market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to new product marketing, such as the unpredictability of market acceptance for new pharmaceutical products and/or the acceptance of new indications for such products; inconsistency of treatment results among patients; potential difficulties in manufacturing a new product; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations. Additional information concerning these and other risk factors can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's 2010 Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
(c) Allergan Ltd. BOTOX(R) is a registered trademark owned by Allergan, Inc.
References:
1) Milsom I et al. How widespread are the symptoms of an overactive bladder
and how are they managed? A population-based prevalence study. BJU International,
2001;87;760-766
2) Irwin DE. et al. Population-Based Survey of Urinary Incontinence, Overactive
Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC
Study. European Urology, 2006;50: 1306-1315
3) Reeves P et al. The current and future burden and cost of overactive bladder
in five European countries. European Urology, 2006; 50: 1050-1057
4) Cruz F et al. Patient attitudes and patterns of treatment utilization in a
European population with overactive bladder symptoms. Eur Urol. 2012;11(Suppl 1):e577
5) Pelletier EM et al. Pharmacotherapy adherence and costs versus
nonpharmacologic management in overactive bladder. Am J Manag Care 2009;15:S108-14
6) D'Souza A et al. Persistence, adherence and switch rates among
extended-release and immediate-release overactive bladder medications in a regional
managed care plan. JMCP, 2008; 14: 291-301
7) Tubaro A. Defining Overactive bladder: Epidemiology and burden of disease.
Urology, 2004; 64 (Suppl 6A): 2-6
8) NIH Consensus and State-of-the-Science Statements, Prevention of Fecal and
Urinary Incontinence in Adults. Dec 12-14 2007:24(1):1-37
http://consensus.nih.gov/2007/incontinen... - Last accessed November
2012
9) Allergan Data On File
10) Allergan Data On File
Media contacts
For further information please contact:
Janet Kettels, Allergan - kettels_janet@allergan.com or +44(0)7738-506-476
Victoria Bramham, CCA London - v.bramham@cca-uk.com or +44(0)207-632-1896
